Immediate Impact
5 standout
Citing Papers
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
2022 Standout
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
2022 Standout
Works of Eli Van Allen being referenced
MA19.01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Eli Van Allen | 2 | 9 | 8 | 3 | 11 | |||
| Zoe Hudson | 2 | 1 | 7 | 7 | 2 | 10 | ||
| Paulina Linares | 2 | 5 | 1 | 9 | 12 | 3 | 15 | |
| J Jimenez Miramón | 2 | 3 | 9 | 8 | 2 | 12 | ||
| Temi Adedoyin | 3 | 9 | 7 | 7 | 5 | 3 | 14 | |
| Kevin M. McBride | 1 | 4 | 8 | 7 | 2 | 9 | ||
| Chun Keat Chew | 3 | 11 | 9 | 2 | 12 | |||
| Yick Ho Lam | 2 | 11 | 2 | 9 | 4 | 3 | 14 | |
| Luis Manuel Domínguez-Parra | 1 | 5 | 2 | 7 | 8 | 2 | 14 | |
| Ayala Hubert | 6 | 10 | 11 | 3 | 11 | |||
| Simbisai Ratcliff | 5 | 7 | 8 | 4 | 9 |
All Works
Loading papers...